All News

It is important to expand clinical trial access for patients with kidney cancer in order to ensure a representative study population.

Intensive chemotherapy improved survival in patients with accelerated and blast phase myeloproliferative neoplasms, with Venclexta showing no clear benefit.

A diagnosis of breast cancer isn’t something most people would think of as a teacher, but sometimes important lessons come to us in unexpected ways.

Cancer treatments can speed up aging in survivors, according to research, which can contribute to a person's risk for conditions like heart disease.

The FDA has granted fast track designation to HLD-0915 for metastatic castration-resistant prostate cancer.

The accelerated approval of Modeyso for diffuse midline glioma with an H3 K27M mutation, is a step in the right direction but more work remains.

Breast cancer survivor and researcher LaShae Rolle studies how individualized strength training during chemo boosts physical, mental and emotional health.

Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years.

More than half of patients with myelofibrosis and low platelets treated with Vonjo saw platelets rise 58% and hemoglobin levels improve.

Dr. Jacob Sands explained that he believes patients should be having more personalized, nuanced conversations with their oncologists.

Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

There are many reliable resources available to patients with kidney cancer, as well as their families and caregivers.

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

Follicular lymphoma survivor Troy Anderson credited acupuncture and nutrition guidance with easing treatment side effects and aided in remission.

Among patients with advanced gastrointestinal stromal tumors, Gleevec and Mektovi was associated with benefits in progression and survival.

When I was diagnosed with peritoneal mesothelioma at 21 years old, the doctors gave me 18 months to live; that was 18 years ago.

About one in six men with grade group 1 prostate cancer have higher-risk disease, showing outcomes vary and biopsy grade may underestimate risk.

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Dr. Aaron Gerds explained when treatment with rusfertide will become accessible for patients with a myeloproliferative neoplasm like polycythemia vera.

I’m a testicular cancer survivor diagnosed at 20. My story is about finding strength, building routines, and sharing hope for those facing cancer.

A nurse with metastatic breast cancer praised biology-guided radiation for her slow-growing squamous cell cancer and the team's thoughtful care.

Long-term follow-up data from the phase 3 MANIFEST 2 clinical trial have been revealed.

Childhood cancer treatments can accelerate biological aging which increases survivors’ risk for long-term health issues like heart disease and obesity.

I was facing rare mesothelioma alone at 21 years old, but sharing my story connected me to a community that offers hope and strength to keep fighting.

The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, review date.

A diverticulitis concern led to a prostate cancer diagnosis that shifted a patient's mindset and highlighted the importance of hisloved ones.

Writing and reading help me stay grounded and find meaning while living with chronic cancer, balancing health, family and speaking out against hatred.

In an interview with CURE, medical oncologist Dr. Ioana Bonta explains why lung cancer is not just a ‘smoker’s disease.’